GSK マネジメント

マネジメント基準チェック /24

GSKの CEO はEmma Walmsleyで、 Apr2017年に任命され、の在任期間は 7.58年です。の年間総報酬は£ 12.72Mで、 10.3%給与と89.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.04%を直接所有しており、その価値は$ 27.33M 。経営陣と取締役会の平均在任期間はそれぞれ6年と3.2年です。

主要情報

Emma Walmsley

最高経営責任者

UK£12.7m

報酬総額

CEO給与比率	10.3%
CEO在任期間	7.6yrs
CEOの所有権	0.04%
経営陣の平均在職期間	6yrs
取締役会の平均在任期間	3.2yrs

経営陣の近況

Recent updates

CEO報酬分析

GSK の収益と比較して、Emma Walmsley の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	UK£3b
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

報酬と市場: Emmaの総報酬 ($USD 15.95M ) は、 AR市場 ($USD 5.73M ) の同規模の企業の平均を上回っています。

報酬と収益: Emmaの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO（最高経営責任者

Emma Walmsley (55 yo)

7.6yrs

在職期間

UK£12,718,000

報酬

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Emma Walmsley	CEO & Director	7.6yrs	UK£12.72m	0.040% $ 27.3m
Julie Brown	CFO & Executive Director	1.6yrs	UK£5.14m	0.0024% $ 1.7m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.8yrs	データなし	データなし
Tony Wood	Chief Scientific Officer and Head of R&D	2.3yrs	データなし	データなし
Sarah Elton-Farr	Head of Investor Relations	no data	データなし	データなし
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.3yrs	データなし	データなし
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.7yrs	データなし	データなし
David Redfern	President of Corporate Development	no data	データなし	データなし
Diana Conrad	Chief People Officer	5.6yrs	データなし	データなし
Philip Thomson	President of Global Affairs	7.6yrs	データなし	0.0057% $ 3.9m
Luke Miels	Chief Commercial Officer	7.2yrs	データなし	データなし
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6.4yrs	データなし	データなし

6.0yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: GSKDの経営陣は経験豊富で経験豊富です（平均在職期間は6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Emma Walmsley	CEO & Director	7.8yrs	UK£12.72m	0.040% $ 27.3m
Julie Brown	CFO & Executive Director	1.5yrs	UK£5.14m	0.0024% $ 1.7m
Jonathan Symonds	Non-Executive Chairman	5.2yrs	UK£765.00k	0.0020% $ 1.3m
Vishal Sikka	Independent Non-Executive Director	2.3yrs	UK£147.00k	0.00036% $ 246.5k
Hal Barron	Non-Executive Director	6.8yrs	UK£356.92k	0.032% $ 22.0m
Harry Dietz	Independent Non-Executive Director	2.8yrs	UK£207.09k	0.00016% $ 109.6k
Anne Beal	Independent Non-Executive Director	3.5yrs	UK£174.93k	0.00017% $ 116.4k
Wendy Mira Becker	Independent Non-Executive Director	1.1yrs	UK£32.00k	0.000040% $ 27.4k
Charles Bancroft	Senior Independent Non-Executive Director	4.5yrs	UK£323.00k	0.0014% $ 979.4k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	データなし	0.000030% $ 20.5k
Elizabeth Anderson	Independent Non-Executive Director	2.2yrs	UK£127.86k	0.000090% $ 61.6k
Jesse Goodman	Independent Non-Executive Director	8.8yrs	UK£173.36k	0.00073% $ 499.9k

3.2yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: GSKDの取締役会は経験豊富であると考えられます ( 3.2年の平均在任期間)。

GSK マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Gsk plc Announces Board Committee Changes

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

Recent updates

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24